UChicago Annual Updates from ASH 2019

 

Videos
16:52

UChicago Annual Updates from ASH 2019

Hereditary Hematopoietic Malignancies: What to Look For, and What to Do When You Find It

FEATURING Michael Drazer
  • 234 views
  • March 20, 2020
  • 2
25:56

UChicago Annual Updates from ASH 2019

Inherited Predisposition to Myeloid Hematologic Malignancies: Why Does Identification of Germline Predisposition Syndromes Matter?

FEATURING Simone Feurstein
  • 53 views
  • March 20, 2020
17:22

UChicago Annual Updates from ASH 2019

BCL2 Inhibition in Myeloid Malignancies: Venetoclax + Azacitidine in AML and MDS & Navitoclax and Ruxolitinib in Ph-MPNs

FEATURING Olatoyosi Odenike
  • 295 views
  • March 20, 2020
12:07

UChicago Annual Updates from ASH 2019

Updates on Myeloid Malignancies: JAK in MF, TGFb Inhibition in MF and MDS & Oral Azanucleosides in AML and MDS & IDH Inhibitors in AML & MPN

FEATURING Olatoyosi Odenike
  • 44 views
  • March 20, 2020
12:13

UChicago Annual Updates from ASH 2019

Highlights from ASH on ALL: Role of AlloSCT in CR1 for Young Adults & Improving Survival Rates in Frontline Treatment of Adults with Ph+ ALL

FEATURING Wendy Stock
  • 41 views
  • March 20, 2020
07:26

UChicago Annual Updates from ASH 2019

Highlight from ASH on ALL: Frontline Therapy in Older Adults & Dual BCL Targeting for Relapse Disease

FEATURING Wendy Stock
  • 33 views
  • March 20, 2020
10:45

UChicago Annual Updates from ASH 2019

Updates on CAR-T Treatment of ALL: Prognosticators of Response, Dual Antigen Targeting, New Approaches to Reduce Toxicity and Improve Durability & Targeting the T-cell With CD5 CAR-T

FEATURING Wendy Stock
  • 30 views
  • March 20, 2020
13:28

UChicago Annual Updates from ASH 2019

ASH 2019 Updates in Multiple Myeloma: Early Intervention in High Risk Smoldering MM & Daratumumab Based Quadruplet Regimens in Newly Diagnosed MM

FEATURING Jagoda Jasielec
  • 108 views
  • March 20, 2020
16:33

UChicago Annual Updates from ASH 2019

ASH 2019 Updates in R/R Multiple Myeloma: Prolonged PFS with KdD, Venetoclax in t(11:14), CAR-T Cell Therapy & BCMA and CD3 Targeted BiTE Antibody

FEATURING Jagoda Jasielec
  • 30 views
  • March 20, 2020
09:30

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in DLBCL: Liso-cel has Favorable Safety Profile With Low Rates of Severe CRS/ICANS

FEATURING Peter Riedell
  • 59 views
  • March 20, 2020
05:40

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in Mantle Cell Lymphoma: KTE-X19 is a New Promising Therapy

FEATURING Peter Riedell
  • 61 views
  • March 20, 2020
13:18

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in CLL/SLL: Liso-cel Active in Pretreated R/R CLL/SLL & Strategies to Mitigate Toxicity in CAR T Cell Therapy

FEATURING Peter Riedell
  • 17 views
  • March 20, 2020
08:12

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on PET Directed Therapy for Early Stage DLBCL

FEATURING Justin Kline
  • 35 views
  • March 20, 2020
12:46

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on FL: Obinutuzimab + Lenalidomide in Frontline Setting & Polatuzumab Combinations and Tazemetostat in R/R FL

FEATURING Justin Kline
  • 127 views
  • March 20, 2020
10:07

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on Hodgkin Lymphoma: Frontline Brentuximab + Nivo in Pts > 60 & PET-adapted Nivo + ICE in First Relapse

FEATURING Justin Kline
  • 313 views
  • March 20, 2020
15:37

UChicago Annual Updates from ASH 2019

ASH 2019 Updates on Treatment of Young 'Fit' CLL Pts: Improved PFS and OS With Ibrutinib + Rituximab & iFCG Regimen Effective for Pts With IGHV Mutations

FEATURING Nitin Jain
  • 727 views
  • March 20, 2020
  • 2
14:45

UChicago Annual Updates from ASH 2019

ASH 2019 Treatment of Older FCR Ineligible CLL Pts: 5 Years Follow‐up on Ibrutinib, Time Limited Therapies & High Rates of Undetectable MRD With Ibrutinib/Venetoclax

FEATURING Nitin Jain
  • 19 views
  • March 20, 2020
09:43

UChicago Annual Updates from ASH 2019

ASH 2019 Updates in R/R CLL: PFS and OS Benefit with VenR, Association of Somatic Mutations with MRD Levels & LOXO-305 Highly Effective

FEATURING Nitin Jain
  • 28 views
  • March 20, 2020